Shanghvi's Sun surprises with loss amid drug slump


MUMBAI: Sun Pharmaceutical Industries Ltd reported its first quarterly loss in at least 12 years after settling an antitrust case in the US amid a global downturn in the generic-drug business.

India’s biggest drugmaker, founded by billionaire Dilip Shanghvi, posted a total loss of 4.25 billion rupees (US$66.3mil) in the three months ended June 30, the Mumbai-based company said in a filing yesterday.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Business , Sun Pharma

   

Next In Business News

Oil gains 1% on hopes of firmer demand
JPMorgan investors weigh CEO Dimon’s strategy, succession plan
Muhibbah rides on Cambodian tourism uptick
Feytech gears up for expansion to meet growing demand
Ready to rise up the ranks again
SC working overtime to combat spread of scams
Russia and Malaysia sign tax agreement
MGB ACHIEVES 23% PROFIT SURGE IN 1Q24
GDP up 4.2% in 1Q24
Chinese firms invest in ‘green’ jet fuel

Others Also Read